East Oregonian

Replicate Bioscience Announces Publication of First-in-Human Data for Its Optimized srRNA Rabies Vaccine in Nature Communications

RBI-4000’s potential to offer a meaningful improvement over existing vaccines for rabies, an ongoing global public health concern, supports further development SAN DIEGO, Feb. 7, 2025 /PRNewswire/ — ...
STAT

Replicate’s srRNA rabies vaccine effective in Phase 1

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello! And it’s Meghana again. Today, we discuss how Biogen’s missed the ...
ksn.com

Replicate Bioscience Announces Publication of Promising New Phase 1 Durability Data for Its srRNA Vaccine Candidate RBI-4000

Eight month follow-up data published in Communications Medicine, a Nature portfolio journal Full clinical dataset supports further development of RBI-4000 as a next generation vaccine approach for ...
FOX8 Cleveland

Replicate Bioscience Initiates a Phase 1 Trial of its Next-Generation srRNA Vaccine

SAN DIEGO, Sept. 12, 2023 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering its novel self-replicating RNA (srRNA) technology to overcome the limitations of current mRNA ...
NBC4 Columbus

Replicate Bioscience and Instituto Butantan Enter Collaborative Agreement to Develop and Commercialize Replicate's Self-Replicating RNA (srRNA) Rabies Vaccine in Latin America

Under the agreement, Instituto Butantan will conduct registrational clinical trials of Replicate's novel srRNA rabies vaccine for post-exposure and pre-exposure prophylaxis Replicate to provide GMP ...